P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL

• Y. Song,
• J. Jin,
• H. Tilly,
• H. Zhang,
• J. Cao,
• J. Feng,
• L. Zhang,
• S. Rai,
• H. Goto,
• Y. Terui,
• W. S. Kim,
• H.-J. Shin,
• J.-P. Gau,
• C.-H. Tsai,
• J. P. Sharman,
• L. Bu,
• J. Hirata,
• C. Lee,
• K. Izutsu,
• J. Zhu

Affiliations

Y. Song

1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing

J. Jin

2 The First Affiliated Hospital of College of Medicine, Zhejiang University, Zhejiang, China

H. Tilly

3 Centre Henri Becquerel and University of Rouen, Rouen, France

H. Zhang

4 Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University, Tianjin

J. Cao

5 Fudan University Shanghai Cancer Center, Shanghai

J. Feng

6 Jiangsu Cancer Hospital, Nanjing

L. Zhang

7 Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China

S. Rai

8 Kindai University Hospital, Osaka

H. Goto

9 Hokkaido University Hospital, Sapporo

Y. Terui

10 The Cancer Institute Hospital of JFCR, Tokyo, Japan

W. S. Kim

11 Samsung Medical Center

H.-J. Shin

12 Pusan National University Hospital, Seoul, South Korea

J.-P. Gau

13 Taipei Veterans General Hospital

C.-H. Tsai

14 National Taiwan University Hospital, Taipei, Taiwan

J. P. Sharman

15 Willamette Valley Cancer Institute/US Oncology, Eugene

L. Bu

16 Genentech, Inc., South San Francisco, United States of America

J. Hirata

16 Genentech, Inc., South San Francisco, United States of America

C. Lee

16 Genentech, Inc., South San Francisco, United States of America

K. Izutsu

17 National Cancer Center Hospital, Tokyo, Japan

J. Zhu

1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing